pH-metric chemical speciation modeling and studies of in vitro antidiabetic effects of bis[(imidazolyl)carboxylato]oxidovanadium(IV) complexes

Gundhla, Isaac Z.; Walmsley, Ryan S.; Ugirinema, Vital; Mnonopi, Nandipha; Hosten, Eric C.; Betz, Richard; Frost, Carminita; Tshentu, Zenixole R.

doi:10.1016/j.jinorgbio.2014.12.019

Cited by 19 publications

(11 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, such study has been mostly limited to the speciation of vanadium in biological media, in which carboxylate ligands are exclusively considered as monodentate ligands. ,,,− ,,− This is partially justified by the fact that these studies were focused on coordination to multifunctional compounds such as glycine, malate, and tartarate. More recently, Gundla et al presented some experimental evidence toward the existence of a 1-alkyl-imidazole-2-carboxylate-vanadium(V) complex in which the carboxylate acts as a bidentate ligand, thus launching the question of how relevant vanadium-acetate linkage isomerism is.…”

Section: Introductionmentioning

confidence: 99%

Roots of Acetate-Vanadium Linkage Isomerism: A QTAIM Study

et al. 2016

View full text Add to dashboard Cite

The possibility of linkage isomerism in a number of vanadium(IV) and vanadium(V) complexes with acetate was surveyed using Density Functional Theory (DFT) and Bader's Quantum Theory of Atoms in Molecules (QTAIM). The results show that vanadium-acetate linkages may be classified as bidentate symmetrical, bidentate asymmetrical, or monodentate, the latter being observed in about 40% of the cases. These latter ones correspond to situations where the two oxygen atoms of the acetate moiety are not equivalent. They are associated with an energy penalty of about 263 kJ·mol(-1), as determined by the distribution of the scaled kinetic energy of the atomic basins forming the acetate ligand. In the presence of bidentate symmetrical vanadium-acetate linkages, the inner valence-shell charge concentrations on the vanadium atom deviate from the traditional VSEPR-derived arrangement, with an energy penalty of about 780 kJ·mol(-1). A compromise situation is partially accomplished in the case of bidentate asymmetrical linkages, which allow a Gillespiean-like arrangement of the inner valence-shell charge concentrations. In this case, one of these local charge concentrations lies close to a V-OAcO bond, which slightly disrupts the equivalence between the two oxygen atoms in the acetate ligand.

show abstract

Section: Introductionmentioning

confidence: 99%

Roots of Acetate-Vanadium Linkage Isomerism: A QTAIM Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The observed differences in the effectiveness of ONS and ONO complexes in the different cell models and mechanisms may be due to the specific or selective effects of these complexes. Differences in the activity of vanadium complexes against on the various cell type have already been observed for bis-coordinated oxidovanadium(IV) complexes with the imidazolyl-carboxylate moiety which improved glucose uptake in cell cultures of myocytes C2C12, adipocytes 3T3-L1 and Chang cells [73]. For example, [VO(Im2COO)2] showed efficacy on 3T3-L1 adipocytes with no activity on C2C12 myocytes.…”

Section: Discussionmentioning

confidence: 91%

“…The absence of a comparator in most published studies poses challenges in comparing the relative activity of the studied vanadium compounds. The more so that the published results of inhibition tests cover a wide range of results, for example IC50 for PTP1B for VOSO4 ranges from 18 nM [73] to 380 nM [74]. This can be explained by differences in the substrate used (e.g.…”

Section: Discussionmentioning

confidence: 99%

Vanadium Complexes with Thioanilidine Derivatives of Aminoacids: Inhibition of Human Phosphatases and Cell-Type Specificity in Various Models of Metabolic Disturbances

Kazek¹,

Głuch‐Lutwin²,

Mordyl³

et al. 2023

Preprint

View full text Add to dashboard Cite

The synthesis and characteristics of the novel ONS-type vanadium(V) complexes with thioanilidine derivatives of aminoacids have been described. They showed inhibition of human protein tyrosine phosphatases (PTP1B, LAR, SHP1 and SHP2) in the submicromolar range and as well as inhibition of non-tyrosine phosphatases (CDC25A and PPA2) similar to bis(maltolato)oxovanadium(IV)(BMOV). The ONS complexes increased [14C]-deoxy-D-glucose transport into C2C12 myocytes, and one of them, VC070 also enhanced this transport in 3T3-L1 adipocytes. These complexes inhibited gluconeogenesis in hepatocytes HepG2, but none of them decreased lipid accumulation in the non-alcoholic fatty liver disease model using the same cells. Compared to the tested ONO-type vanadium complexes with 5-bromosalicylaldehyde and substituted benzhydrazides as components of Schiff base ligand, the ONS complexes revealed stronger inhibition of protein tyrosine phosphatases, but the ONO complexes showed greater activity in the cell models, in general. Moreover, the most of the active complexes from both groups showed better effects than VOSO4 and BMOV. Complexes from both groups activated AKT and ERK signaling pathway in hepatocytes to a comparable extent. One of the ONO complexes, VC068, showed activity in all above models, including also glucose utilization in the myocytes and glucose transport in insulin-resistant hepatocytes. The discussion has put forward explications for the results within the wider scope of the knowledge about vanadium complexes.

show abstract

“…49,50 Anti-diabetic activity of some metal complexes like vanadium, copper and zinc complexes have been studied and shown promising activities. [51][52][53] Recently in vivo anti-diabetic activities of zinc coordination compounds have also been reported. 53 However, although organotin(IV) complexes have shown potential biological properties such as anti-tumour, anticancer, larvicidal, anti-bacterial, antifungal, anti-tuberculosis etc., [15][16][17][18][19][20][21][22][23] investigation of the anti-diabetic activity of organotin(IV) complexes remains largely unexplored except for a very recent report on triorganotin(IV) azo-carboxylates by our group.…”

Section: Anti-diabetic Activitymentioning

confidence: 99%